After taking a hard look at the data, Novartis punts Aduro’s STING drug — the latest in a long line of setbacks
Things keep getting worse at the beleaguered Aduro.
Ten months after CEO Stephen Isaacs was forced to restructure and downsize the staff after a series of setbacks, Novartis is dumping Aduro’s lead surviving drug after concluding from the clinical data that there was no reason to push forward.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.